Table 1 Antibody avidity over time among one-dose and three-dose participants who were HPV16 seronegative at first HPV vaccination.

From: HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial

  

One-dose (N = 747 samples)

Three-dose (N = 1115 samples)

One-dose/Three-dose

Year of follow-up

n

GMA (95% CI)

IQR

% change†

n

GMA (95% CI)

IQR

% change†

Ratio (95% CI)

Year 1

52

2.39 (2.13–2.68)

2.25–3.07

N/A

161

2.87 (2.80–2.94)

2.68–3.16

N/A

0.83 (0.74–0.94)

Year 2

56

2.62 (2.44–2.82)

2.34–3.10

9.8

142

2.99 (2.89–3.09)

2.82–3.31

4.0

0.88 (0.81–0.95)

Year 3

51

2.81 (2.67–2.96)

2.60–3.11

7.2

119

2.98 (2.90–3.07)

2.84–3.31

−0.2

0.94 (0.89–1.00)

Year 4

123

2.76 (2.62–2.90)

2.65–3.13

−1.9

191

3.02 (2.97–3.07)

2.87–3.26

1.2

0.91 (0.87–0.96)

Year 7

162

2.76 (2.66–2.86)

2.54–3.15

0.1

225

3.07 (3.01–3.13)

2.94–3.40

1.8

0.90 (0.86–0.94)

Year 9

125

2.73 (2.55–2.92)

2.58–3.16

−1.1

136

3.05 (2.98–3.12)

2.96–3.32

−0.8

0.90 (0.83–0.96)

Year 11

178

2.70 (2.60–2.80)

2.46–3.08

−1.2

141

3.02 (2.94–3.11)

2.89–3.32

−0.8

0.89 (0.85–0.93)

p-for-trend*

 

0.28

   

0.85

   
  1. N total number of samples, n number of samples tested per study visit, GMA Geometric Mean of the Avidity Index, IQR interquartile range, CI confidence intervals, N/A not applicable.
  2. †% change was calculated based on two consecutive visits.
  3. *p-for-trend within dose group, over time in years 4–11.
Back to article page